Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation?
暂无分享,去创建一个
P. Riederer | P. Riederer | R. Ravid | T. Arendt | G. Münch | E. Hirsch | R. Ravid | G. Münch | H. J. Lüth | A. Wong | Th. Arendt | E. Hirsch | H. Lüth | A. Wong | G. Münch
[1] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[2] P. Riederer,et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression , 1999 .
[3] P. Riederer,et al. Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.
[4] G. Perry,et al. Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.
[5] R. Khalifah,et al. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.
[6] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[7] B. Hyman,et al. α-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining , 2000, Acta Neuropathologica.
[8] G. Perry,et al. Early contribution of oxidative glycation in Alzheimer disease , 1996, Neuroscience Letters.
[9] Paul J Thornalley. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. , 1998, Chemico-biological interactions.
[10] E. Braak,et al. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease , 1998, Brain Research.
[11] R. Krüger,et al. Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders , 2000, Journal of neural transmission.
[12] P. Riederer,et al. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[13] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[14] M. Smith,et al. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease , 1996, Brain Research.
[15] G. Münch,et al. Distribution of advanced glycation end products in the cerebellar neurons of dogs , 1998, Brain Research.
[16] P. Riederer,et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.
[17] J. Eaton,et al. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. , 1998, Biochemical and biophysical research communications.
[18] M. Brownlee,et al. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. , 1990, Biochemical and biophysical research communications.
[19] P Riederer,et al. Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? , 1998, Annals of neurology.
[20] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[21] P. Riederer,et al. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. , 2000, European journal of biochemistry.
[22] J. Thome,et al. Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.
[23] P. Riederer,et al. Understanding Parkinson's disease. , 1997, Scientific American.
[24] P. Riederer,et al. Parkinson's disease: a major hypokinetic basal ganglia disorder , 1999, Journal of Neural Transmission.
[25] H. Braak,et al. Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.